Arch Oncology Appoints Kirk Christoffersen as Chief Business Officer

BRISBANE, Calif. & ST. LOUIS–(BUSINESS WIRE)–Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on
the discovery and development of best-in-class anti-CD47 antibody
therapies, today announced the appointment of Kirk Christoffersen as
Chief Business Officer. In this newly-created position, Mr.
Christoffersen will lead Arch Oncology’s corporate strategy and other
business functions reporting to Julie Cherrington, Ph.D., President and
Chief Executive Officer of Arch Oncology.

“Kirk has an exceptionally strong background in business and corporate
development, strategic planning, and operations which will be valuable
as we further advance our pipeline of novel antibody therapies,” said
Julie M. Cherrington, Ph.D., President and Chief Executive Officer of
Arch Oncology. “His leadership experience and track record will help
drive opportunities to create value at Arch Oncology. We welcome Kirk to
the team and look forward to his contributions as we develop our
pipeline of therapies to help patients with cancer.”

Kirk Christoffersen added, “It is an exciting time to join Arch Oncology
as there is significant momentum across the business. There is a growing
body of data on AO-176 and the pipeline, an advancing Phase 1 clinical
trial for AO-176, and recent backing from leading investors in a
successful Series B financing round. Julie has assembled a great team
and I am eager to get to work to help unlock additional value creation
opportunities for Arch Oncology and the patients we aim to serve.”

Kirk Christoffersen has over 20 years of experience in the
biopharmaceutical industry. Before joining Arch Oncology, he was Senior
Vice President, Corporate and Business Development for Compugen.
Previously, he worked at GlobeImmune, Inc. for over a decade in roles of
increasing responsibility becoming Vice President, Corporate
Development. Earlier in his career, Mr. Christoffersen held leadership
positions in corporate development and marketing at OSI Pharmaceuticals,
Gilead Sciences, and NeXstar Pharmaceuticals. Mr. Christoffersen earned
an undergraduate degree from the University of Michigan and an M.B.A.
from the Daniels College of Business at the University of Denver.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology
company focused on the discovery and development of best-in-class
antibody therapies for the treatment of patients with cancer. The
Company’s next-generation anti-CD47 antibodies are highly
differentiated, with the potential to improve upon the safety and
efficacy profile relative to other agents in this class. Arch Oncology’s
lead product candidate AO-176 is in a Phase 1 clinical trial for the
treatment of patients with select solid tumors. In addition, the Company
is advancing a number of pipeline programs, including anti-signal
regulatory protein (SIRP) antibodies. Arch Oncology’s leadership team
has successfully developed new drugs for patients before and is backed
by leading investors, including RiverVest Venture Partners, Roche
Venture Fund, 3×5 RiverVest Partners II-B, and Lightchain. For more
information please visit www.archoncology.com.

Contacts

Amy Figueroa, CFA
For Arch Oncology
[email protected]
650-823-2704